Shanghai Allist Pharmaceuticals Co., Ltd. (SHA:688578)
China · Delayed Price · Currency is CNY 111.58
+5.33 (5.02%)
Sep 30, 2026, 3:00 PM CST
SHA:688578 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 50,211 | 46,868 | 26,955 | 18,747 | 8,856 | 13,590 | |
Market Cap Growth | 5.41% | 73.87% | 43.78% | 111.69% | -34.83% | 6.04% |
Enterprise Value | 45,975 | 43,593 | 23,927 | 16,494 | 6,916 | 11,015 |
Last Close Price | 111.58 | 102.88 | 58.72 | 40.34 | 19.06 | 29.25 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 18.79 | 21.41 | 18.85 | 29.10 | 67.85 | 743.66 |
Forward PE | 17.43 | 22.45 | 17.64 | 28.70 | 74.26 | 109.82 |
PS Ratio | 8.19 | 9.04 | 7.58 | 9.29 | 11.20 | 25.64 |
PB Ratio | 5.93 | 6.62 | 5.10 | 4.71 | 2.78 | 4.57 |
P/TBV Ratio | 6.05 | 6.79 | 5.17 | 4.79 | 2.84 | 4.68 |
P/FCF Ratio | 19.70 | 21.94 | 20.80 | 30.90 | - | - |
P/OCF Ratio | 18.77 | 20.18 | 17.21 | 27.79 | 96.65 | 463.96 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 7.50 | 8.40 | 6.73 | 8.17 | 8.74 | 20.78 |
EV/EBITDA Ratio | 16.95 | 18.66 | 15.83 | 28.18 | 117.62 | - |
EV/EBIT Ratio | 17.25 | 18.98 | 16.22 | 30.08 | 179.00 | - |
EV/FCF Ratio | 18.04 | 20.40 | 18.47 | 27.18 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.00 | 0.00 | 0 | 0 | 0.00 | 0.00 |
Debt / EBITDA Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | - |
Debt / FCF Ratio | 0.00 | 0.00 | 0.00 | 0.00 | - | - |
Net Debt / Equity Ratio | -0.50 | -0.50 | -0.69 | -0.63 | -0.64 | -0.76 |
Net Debt / EBITDA Ratio | -1.56 | -1.52 | -2.40 | -4.29 | -34.61 | 40.26 |
Net Debt / FCF Ratio | -1.66 | -1.66 | -2.80 | -4.14 | 38.99 | 13.84 |
Asset Turnover | 0.75 | 0.75 | 0.69 | 0.52 | 0.24 | 0.17 |
Inventory Turnover | 4.10 | 3.22 | 3.07 | 1.64 | 1.78 | 1.90 |
Quick Ratio | 5.14 | 4.92 | 6.73 | 7.18 | 8.62 | 14.59 |
Current Ratio | 5.37 | 5.18 | 6.96 | 7.46 | 8.98 | 15.21 |
Return on Equity (ROE) | 36.71% | 35.41% | 30.86% | 17.97% | 4.24% | 0.63% |
Return on Assets (ROA) | 20.29% | 20.77% | 17.91% | 8.77% | 0.73% | -1.43% |
Return on Invested Capital (ROIC) | 52.08% | 76.00% | 83.25% | 41.02% | 4.13% | -13.89% |
Return on Capital Employed (ROCE) | 31.40% | 32.40% | 27.70% | 13.80% | 1.20% | -2.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 5.33% | 4.67% | 5.30% | 3.44% | 1.47% | 0.13% |
FCF Yield | 5.07% | 4.56% | 4.81% | 3.24% | -0.59% | -1.20% |
Dividend Yield | 1.07% | 0.97% | 1.11% | 0.99% | - | - |
Payout Ratio | 16.80% | 16.45% | 20.46% | - | - | - |
Buyback Yield / Dilution | -0.34% | -0.18% | 0.18% | -0.09% | 1.49% | -23.59% |
Total Shareholder Return | 0.74% | 0.80% | 1.29% | 0.90% | 1.49% | -23.59% |